Pharmacy Compounding Advisory Committee Votes Mostly In Unison
Executive Summary
In first meeting after multi-year absence, FDA’s Pharmacy Compounding Advisory Committee takes 33 votes on do-not-compound and bulk substances lists.
You may also be interested in...
FDA Forced To Update Approved Products List In Do-Not-Compound Review
ANDAs mistakenly still are cataloged as approved even though they have been withdrawn from marketing.
US FDA’s Standard Application Assessment Makes A Comeback
After years where many more applications received priority assessments than standard assessments, in FY 2022 the difference narrowed.
Gene Therapy: Nonclinical Questions Do Not Seem Ideal For The US FDA’s New Type D Meeting
Nonclinical testing questions should be answered in a pre-IND meeting, rather than the new Type D session. A US FDA Center for Biologics Evaluation and Research official also indicated support for alternatives to animal testing when possible.